Prothena Corp plc 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 Commission file number:001-35676______________________________________ PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter)______________________________________ 98-1111119(I.R.S. EmployerIdentification Number) Ireland(State or other jurisdiction ofincorporation or organization) Registrant’s telephone number, including area code:011-353-1-236-2500______________________________________ Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and(2)has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filer☒Non-accelerated filer☐ Accelerated filerSmallerreportingcompanyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ The number of ordinary shares outstanding was53,829,982asof July25, 2025. PROTHENA CORPORATION PLCForm 10-Q – QUARTERLY REPORTFor the Quarter Ended June30, 2025 TABLE OF CONTENTS PART I. FINANCIAL INFORMATION1Item1. Financial Statements (unaudited)1Condensed Consolidated Balance Sheets as of June30, 2025 and December31, 20241Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 20242Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 20243Condensed Consolidated Statements of Shareholders' Equity for the three and six months ended June 30, 2025 and20245Notes to Condensed Consolidated Financial Statements6Item2. Management’s Discussion and Analysis of Financial Condition and Results of Operations24Item3. Quantitative and Qualitative Disclosures About Market Risk35Item4. Controls and Procedures35 Item1. Legal ProceedingsItem1A. Risk FactorsItem2. Unregistered Sales of Equity Securities and Use of ProceedsItem3. Defaults Upon Senior SecuritiesItem4. Mine Safety DisclosuresItem5. Other InformationItem6. Exhibits SIGNATURESEXHIBIT INDEX Note Regarding Forward-Looking Statements In addition to historical information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning ofSection21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include words such as “aim,”“anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective”“plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictionsof or indicate future events and future trends, or the negative of these terms or other comparable terminology. In addition, any statementsthat refer to expectations, projections, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements, which reflect our beliefs, assumptions, expectations, estimates, forecasts, and projections aboutour business and the industry in which we operated as of the date hereof, are estimates based on our best judgment. These statements relateto, among other things, our goal to continue building a biology-directed discovery engine targeting protein dysregulation; the treatmentpotential, designs, proposed mechanisms of action, and potential administration of our drug candidates; potential indications and attributesof epitopes and antibodies we have identified in our programs; plans for ongoing and future clinical trials of our drug candidates; ourpotential to advance, initiate, and complete investigational new drug (“IND”) enabling studies for our discovery and preclinical programs;the expected timing of reporting data from clinical trials of our drug candidates, including initial data in August 2025 from our